Abatacept now approved for rheumatoid arthritis after failure of conventional DMARDs

Following a review, NICE have overturned their previous negative decision for abatacept (Orencia) following the introduction of a patient access scheme.

This new guidance brings the drug in line with other anti-TNF drugs licensed for the treatment of rheumatoid arthritis (pictured) that have been approved by NICE for NHS use | SCIENCE PHOTO LIBRARY
This new guidance brings the drug in line with other anti-TNF drugs licensed for the treatment of rheumatoid arthritis (pictured) that have been approved by NICE for NHS use | SCIENCE PHOTO LIBRARY

Previously, abatacept was only approved for use in rheumatoid arthritis after the failure of a TNF inhibitor. Now it may also be used in adults whose disease has responded inadequately to 2 conventional disease-modifying anti-rheumatic drugs (DMARDs), including methotrexate, provided the manufacturer supplies abatacept with the discount agreed in the patient access scheme.

View Orencia drug record

NICE guidance on abatacept in rheumatoid arthritis after failure of conventional DMARDS

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Women taking valproate still unaware of pregnancy risks, survey finds

Women taking valproate still unaware of pregnancy risks, survey finds

One in ten women currently taking valproate are unaware...

Experts urge vitamin D supplementation and call for research into possible COVID-19 benefits
Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...